Fig. 3From: Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world settinga Evolution of LVEF during follow-up in patients with newly diagnosed NICM with LVEF ≤35% (mean ± SD). b Evolution of LVEF/ICD indication in patients with newly diagnosed NICM with LVEF ≤ 35%Back to article page